Selepressin

At a glance

Overview

Vasopressin affects both vascular tone and kidney water retention through different receptors. Selepressin was designed to favor the vascular V1a pathway and avoid some V2-mediated effects. This supplied a rationale for investigating whether more selective signaling could reduce organ support needs in septic shock. The development program progressed beyond small hemodynamic experiments to the adaptive SEPSIS-ACT randomized trial. That study tested a meaningful combined outcome of days alive and free of ventilation and vasopressors. Its negative result is central to the profile and cannot be replaced by an assumption that receptor selectivity must produce a clinical advantage over existing vasopressor care.

Supporting sources [1] [2]

How it works

Selepressin stimulates V1a receptors on vascular smooth muscle, increasing vascular tone through intracellular calcium signaling. Relative V1a selectivity was intended to separate pressor effects from V2-associated water retention and other vasopressin actions. However, a cleaner receptor profile does not automatically improve survival or organ recovery. Vasoconstriction may still alter regional perfusion, and the clinical consequence depends on illness, exposure, and concomitant treatment.

Supporting sources [1] [2]

What the adaptive trial found

SEPSIS-ACT treated 828 participants and stopped after its first part for futility. Selepressin did not significantly improve ventilator- and vasopressor-free days compared with placebo added to background care. The trial also did not show significant benefit in key secondary outcomes including 90-day mortality or kidney-replacement-therapy-free days.

Supporting sources [1]

Why the endpoint is more informative than pressure alone

The protocol was designed to test whether a pressor strategy translated into less organ support while accounting for death. That is a broader clinical question than whether the drug can raise arterial pressure. The adaptive design allowed early termination when the probability of success was inadequate, limiting unnecessary further exposure.

Supporting sources [2]

Selective receptors do not remove ischemic concerns

Cardiac arrhythmia and ischemic events were monitored in the trial, including cardiac, mesenteric, and peripheral ischemia. Event comparisons did not establish a decisive clinical advantage. The monitored intensive-care setting and short exposure also limit conclusions about any unrelated outpatient or chronic use.

Supporting sources [1]

Is it an approved replacement for vasopressin?

No. The reviewed development program does not establish an approved US selepressin medicine or routine septic-shock indication. Vasopressin’s approval and familiarity cannot be transferred to this modified analog. Any future role would require new evidence addressing a specific population and clinically meaningful outcomes.

Supporting sources [1] [2]